Gene Therapy Market to be dominated by Non-Viral Vectors through 2028

Increase in the number of cases of cancer and other chronic diseases is expected to drive the Global Gene Therapy Market growth in the forecast period, 2024-2028.

According to TechSci Research report, “Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F”, Global Gene Therapy Market has valued at USD 6.01 Billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 9.26% through 2028. The market for Gene Therapy devices has witnessed consistent growth over the forecast period due to an increasingly strong product portfolio, expanding investments by key market players, and a high prevalence of target diseases and interest in innovative and new therapy. Furthermore, the increased investment in research and development by government and private organizations will create further prospects for the growth of the gene therapy market during the forecast period. The rapid technological advancements in cellular and molecular biology in genomics research have contributed greatly to the growing gene therapy market in recent years. In many industrialized countries, the frequency of cardiovascular diseases is increasing, and there is a growing need to cure these diseases in less time, resulting in players investing extensively in the research and development of highly effective and innovative therapeutics such as gene therapy. The prevalence of rare diseases such as cardiovascular and cancer diseases will have a positive impact on the demand for gene therapy applications.

Also, technical challenges involve intricate processes of gene delivery, integration, and expression within the target cells which can hamper the growth of Global Gene Therapy Market. Similarly, High Development Costs can restrain the growth of Global Gene Therapy Market. Additionally, Regulatory Hurdles and Limited Manufacturing Scalability will further restrict the growth of Global Gene Therapy Market.

Browse over xx market data Figures spread through xx Pages and an in-depth TOC on "Global Gene Therapy Market.”

The Global Gene Therapy Market is segmented into Vector Type, Delivery Method, Indication and Region.

Based on Indication, Global Gene Therapy market is segmented into Rare Diseases, Cancer, Neurological Diseases, Others. The Cancer segment accounted for the largest revenue share in 2022 and is expected to exhibit a rapid CAGR over the forecast period. This can be attributed due to the availability of many gene therapy products that can be used to treat cancer and a larger patient population. The invention in gene therapy for cardiovascular and rare disease treatment is raising awareness regarding the capability of gene therapy to cure diseases. This is one of the major factors responsible for the market’s positive growth.

Major companies operating in Global Gene Therapy Market are:

• REGENXBIO Inc.
• Oxford Biomedica PLC.
• Voyager Therapeutics Inc.
• Human Stem Cells Institute
• Dimension Therapeutics, Inc.
• Bristol-Myers Squibb Company
• Sanofi-Aventis
• Applied genetic technologies corporation.
• Hoffmann-la roche ltd.
• Bluebird bio, inc.
• Novartis ag
• Uniqure n.v.

In July 2021, bluebird Bio Inc. announced its strategic alliance with National Resilience Inc. to develop next generation cell and gene therapies for modifying cell materials to provide treatment for diseases.

In July 2021, Orchard Therapeutics announced its collaboration with Pharming Group for the commercialization, and development of HSC gene therapy for the treatment of hereditary angioedema.

In June 2021, UniQure NV acquired Corlieve Therapeutics for implementing the AMT-260 program of Corlieve to provide temporal lobe epilepsy (TLE) treatment. The AMT-260 program is a gene therapy that uses miRNA silencing technology to target kainite receptors in patients with TLE.

In February 2021, Spark Therapeutics announced that the first study participant had been dosed in the US region as a part of international gene therapy clinical trial related to Pompe disease.

In June 2021, Biogen Inc. announced positive results from their phase 3-star study of their timrepigene emparvovec, an investigational gene therapy treatment of choroideremia.

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The North America region is expected to witness significant growth of Global Gene Therapy market due to the several government organizations supporting research campaigns around the country, owing to the robust regulatory framework for cellular treatment development and the substantial presence of biopharmaceutical businesses. Furthermore, the presence of modern healthcare infrastructure, availability of reimbursements, and the presence of significant industry players in the region is a key driver in shaping the future of this dynamic field. The key market players can expect profitable growth possibilities as research and development investments are rising at a rapid pace. In addition, the market players are implementing key marketing strategies for the growth and development of the gene therapy market during the forecast period” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Vector Type (Viral Vector, Non-Viral Vector), By Delivery Method (In-Vivo, Ex-Vivo), By Indication (Rare Diseases, Cancer, Neurological Diseases, Others), By Region and Competition”, has evaluated the future growth potential of Global Gene Therapy Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Gene Therapy Market.

Contact
Mr. Ken Mathews
TechSci Research LLC
420 Lexington Avenue,
Suite 300, New York,
United States- 10170
M: +13322586602
Email: [email protected]
Website: https://www.techsciresearch.com